Serum insulin‐like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma‐associated malnutrition and muscle wasting

Malnutrition and muscle wasting are common features frequently observed in pancreatic ductal adenocarcinoma (PDAC) patients with cancer cachexia. They are associated with reduced survival and quality of life. Nutrition therapy is an important part of multimodal cancer care in PDAC. However, due to the complexity of nutrition assessment, only 30–60% of patients with nutritional risks receive nutritional treatment at present. It is important to identify biomarkers that may be used to improve management of PDAC‐associated malnutrition. Serum insulin‐like growth factor binding protein 2 (IGFBP2) has emerged as a potential serum biomarker in a variety of tumours. However, its association with malnutrition and muscle wasting in PDAC is unclear.

[1]  Yueying Li,et al.  Serum IGFBP2 Level Is a New Candidate Biomarker of Severe Malnutrition in Advanced Lung Cancer , 2020, Nutrition and cancer.

[2]  M. Karamouzis,et al.  Pancreatic Cancer and Cachexia—Metabolic Mechanisms and Novel Insights , 2020, Nutrients.

[3]  Swarnali Acharyya,et al.  Understanding cachexia in the context of metastatic progression , 2020, Nature Reviews Cancer.

[4]  R. Medeiros,et al.  Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia , 2020, Journal of cachexia, sarcopenia and muscle.

[5]  G. Fuller,et al.  IGFBP2: integrative hub of developmental and oncogenic signaling network , 2020, Oncogene.

[6]  Guohao Wu,et al.  Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: A prospective cohort study. , 2019, Clinical nutrition.

[7]  J. Prados,et al.  The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview , 2019, Cancer biology & medicine.

[8]  J. Trevino,et al.  Molecular therapeutic strategies targeting pancreatic cancer induced cachexia , 2018, World journal of gastrointestinal surgery.

[9]  S. Herzig,et al.  Cancer Cachexia: More Than Skeletal Muscle Wasting. , 2018, Trends in cancer.

[10]  S. Theocharis,et al.  Clinical Value of Nutritional Status in Cancer: What is its Impact and how it Affects Disease Progression and Prognosis? , 2017, Nutrition and cancer.

[11]  F. Ottery,et al.  Assessing nutritional status in cancer: role of the Patient-Generated Subjective Global Assessment , 2017, Current opinion in clinical nutrition and metabolic care.

[12]  Wei Zhang,et al.  IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. , 2016, Cancer research.

[13]  Zhou Yuan,et al.  Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wasting , 2016, Journal of Experimental & Clinical Cancer Research.

[14]  L. Jia,et al.  Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes , 2016, Oncotarget.

[15]  Lun Zhang,et al.  IGF-binding protein 2 is a candidate target of therapeutic potential in cancer , 2016, Tumor Biology.

[16]  Y. Bang,et al.  Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index , 2015, PloS one.

[17]  G. Mantovani,et al.  Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. , 2015, Future oncology.

[18]  N. Perrimon,et al.  Systemic organ wasting induced by localized expression of the secreted insulin/IGF antagonist ImpL2. , 2015, Developmental cell.

[19]  D. McCance,et al.  IGF-Binding Protein 2 – Oncogene or Tumor Suppressor? , 2015, Front. Endocrinol..

[20]  Yan Sun,et al.  Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. , 2014, Carcinogenesis.

[21]  M. Martignoni,et al.  Cachexia and pancreatic cancer: are there treatment options? , 2014, World journal of gastroenterology.

[22]  K. Boucher,et al.  Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[23]  S. Lo,et al.  Pancreatic cancer cachexia: a review of mechanisms and therapeutics , 2014, Front. Physiol..

[24]  N. Perrimon,et al.  Mechanisms of muscle growth and atrophy in mammals and Drosophila , 2014, Developmental dynamics : an official publication of the American Association of Anatomists.

[25]  Xifeng Wu,et al.  Insulin-Like Growth Factor Binding Protein-2 Level Is Increased in Blood of Lung Cancer Patients and Associated with Poor Survival , 2013, PloS one.

[26]  L. Mccargar,et al.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Yun-Ru Chen,et al.  Development of IGF Signaling Antibody Arrays for the Identification of Hepatocellular Carcinoma Biomarkers , 2012, PloS one.

[28]  J. Sabate,et al.  Malnutrition Is High and Underestimated During Chemotherapy in Gastrointestinal Cancer: An AGEO Prospective Cross-Sectional Multicenter Study , 2012, Nutrition and cancer.

[29]  C. Bloomfield,et al.  High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. , 2011, Leukemia research.

[30]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[31]  D. Cella,et al.  Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. , 2011, Annual review of medicine.

[32]  Hsiu‐Po Wang,et al.  Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[33]  Y. Ishikawa,et al.  Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. , 2010, The American journal of pathology.

[34]  Wei Zhang,et al.  Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. , 2009, Neuro-oncology.

[35]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[36]  P. Marques‐Vidal,et al.  Serum concentrations of TNF-alpha as a surrogate marker for malnutrition and worse quality of life in patients with gastric cancer. , 2007, Clinical nutrition.

[37]  M. Stampfer,et al.  Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts , 2007, British Journal of Cancer.

[38]  Xiao-qun Zhu,et al.  Expression of insulin-like growth factor binding protein-2 in gastric carcinoma and its relationship with cell proliferation. , 2006, World journal of gastroenterology.

[39]  Stanley Heshka,et al.  Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. , 2004, Journal of applied physiology.

[40]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[41]  A. Inui.  Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management , 2002, CA: a cancer journal for clinicians.

[42]  M. Kattan,et al.  Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[44]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[45]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[46]  Hang-bo Zhou,et al.  Expression of IGFBP2 in Gastric Carcinoma and Relationship With Clinicopathologic Parameters and Cell Proliferation , 2006, Digestive Diseases and Sciences.

[47]  C. Potten,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Circulating Insulin-Like Growth Factor II and , 2000 .

[48]  Stampfer,et al.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. , 1999, Journal of the National Cancer Institute.